Leptin-induced increase in blood pressure and markers of endothelial activation during pregnancy in Sprague Dawley rats is prevented by resibufogenin, a marinobufagenin antagonist

New Insights on the Role of Marinobufagenin from Bench to Bedside in Cardiovascular and Kidney Diseases

Marinobufagenin (MBG) is a member of the bufadienolide family of compounds, which are natural cardiac glycosides found in a variety of animal species, including man, which have different physiological and biochemical functions but have a common action on the inhibition of the adenosine triphosphatase sodium-potassium pump (Na+/K+-ATPase). MBG acts as an endogenous cardiotonic steroid, and in the last decade, its role as a pathogenic factor in various human diseases has emerged. In this paper, we have collated major evidence regarding the biological characteristics and functions of MBG and its implications in human pathology. This review focused on MBG involvement in chronic kidney disease, including end-stage renal disease, cardiovascular diseases, sex and gender medicine, and its actions on the nervous and immune systems. The role of MBG in pathogenesis and the development of a wide range of pathological conditions indicate that this endogenous peptide could be used in the future as a diagnostic biomarker and/or therapeutic target, opening important avenues of scientific research.

Systematic Review of Literature Documenting the Link Between BMI, Sperm Parameters, and Leptin

Background: Leptin administration to rats causes adverse effects on sperm that resemble those reported in obese males. The purpose of this review is, therefore, to examine whether human and animal studies have taken this information on board and have attempted to link the poor sperm quality in obese or overweight individuals to leptin in their methodology, data analysis, and discussion. The review also documents the link between low sperm quality in the obese and leptin.

Method: A search was made for articles reporting body mass index (BMI), sperm parameters, and leptin, published until September 2020 in PubMed, Science Direct, Google Scholar, and Springer Link using a number of search terms.

Results: Forty-four of the 53 human and animal studies on BMI and sperm parameters reported abnormal sperm parameters in the obese but only 9 of those had measured serum leptin. None, however, attempted to link sperm abnormalities to leptin. Nine animal studies report of adverse effects of leptin on sperm in normal weight rats that were found to be similar to those reported in obese males.

Conclusion: Although none of the human studies had actually linked the raised leptin to sperm abnormalities in the obese, there is nevertheless, convincing evidence linking leptin to obesity-related poor sperm quality and male infertility. There is a need, therefore, to include measures that will help reduce the impact of raised leptin levels on male reproductive function, particularly, in obese infertile or subfertile males.

Epigallocatechin gallate decreases plasma triglyceride, blood pressure, and serum kisspeptin in obese human subjects

Obesity is one of major risk factors increasing chronic diseases including type II diabetes, cardiovascular diseases, and hypertension. The effects of epigallocatechin gallate (EGCG), the major active compound in green tea, on reduced obesity and improved metabolic profiles are still controversial. Furthermore, the effects of EGCG on human adipocyte lipolysis and browning of white adipocytes have not been elucidated. This study aimed to investigate the effects of EGCG on obesity, lipolysis, and browning of human white adipocytes. The results showed that, when compared to the baseline values, EGCG significantly decreased fasting plasma triglyceride levels (P < 0.05), systolic blood pressure (P < 0.05), diastolic blood pressure (P < 0.05), and serum kisspeptin levels (P < 0.05) after 8 weeks of supplement. On the other hand, supplement of EGCG in obese human subjects for 4 or 8 weeks did not decrease body weight, body mass index, waist and hip circumferences, nor total body fat mass or percentage when compared to their baseline values. The study in human adipocytes showed that EGCG did not increase the glycerol release when compared to vehicle, suggesting that it had no lipolytic effect. Furthermore, treatment of EGCG did not enhance uncoupling protein 1 (UCP1) mRNA expression in human white adipocytes when compared with treatment of pioglitazone, the peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, suggesting that EGCG did not augment the browning effect of PPAR-γ on white adipocytes. This study revealed that EGCG reduced 2 metabolic risk factors which are triglyceride and blood pressure in the human experiment. We also showed a novel evidence that EGCG decreased kisspeptin levels. However, EGCG had no effects on obesity reduction in humans, lipolysis, nor browning of human white adipocytes.